PathAI presents data on using AI to aid liver research and NASH drug development

Pathology-focused AI company PathAI will present findings on the use of machine learning (ML) to enhance the scoring of nonalcoholic steatohepatitis (NASH) at the 2022 AASLD 2022 Liver Meeting.

The AASLD 2022 Liver Meeting is Nov. 4–8 in Washington, D.C., where the  company will share five presentations. Boston-based PathAI developed four of them with pharmaceutical collaborators. 

An oral presentation jointly developed with Gilead Sciences (Nasdaq:GILD) will touch on using exploratory analyses of NASH histology with CRN scores informed by a multi-stain ML technique. The companies will explain how a new ML-based scoring model pulling data from images stained with hematoxylin and eosin (H&E) and Masson’s Trichrome can predict NASH CRN grades and stages. 

According to the presenters, the new technique has potential to reduce the high variability found in the current evaluation process of NASH biopsies. The method incorporates data from multiple …

Read more
  • 0